Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision
Conclusions
The baseline BCVA–LLVA gap is a significant predictor of visual acuity response to anti-VEGF treatment in patients with wAMD.
Trial registration number
NCT00891735; Post-results.
Source: British Journal of Ophthalmology - Category: Opthalmology Authors: Frenkel, R. E. P., Shapiro, H., Stoilov, I. Tags: Retina, Open access Original articles - Clinical science Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Diabetes | Endocrinology | Lucentis | Opthalmology | Ranibizumab Injection | Science | Study